Long-term Follow-up Results of CT-guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer.
To examine whether CT-guided daily adaptive radiation therapy (ART) can be safely administered against localized prostate cancer. Twenty-six patients with localized prostate adenocarcinoma were irradiated through opposed AP/PA fields up to 46 Gy, then CT-guided daily ART was performed through opposed lateral fields until 76 Gy at 2 Gy/fraction. Biochemical relapse-free survival was 89% at 3 years and 85% at 5 years and 76% at 7 years after ART, respectively. The 3-, 5- and 7-year local relapse-free survival rates were 100%, 100% and 95%, respectively. The 5-year incidence rates of grade 1 and 2 late gastrointestinal adverse events were 15.4% (n=4) and 3.8% (n=1), respectively, and those of grade 1 and 2 late genitourinary adverse events were 3.8% (n=1) and 0% (n=0), respectively. CT-guided daily ART was well tolerated and suggested a good long-term tumor control with minimal adverse events.